The use of BTK inhibitors in treating B-cell malignancies and autoimmune diseases spans a broad spectrum of patient demographics, including variations in age and gender. Understanding these demographics is critical for optimizing treatment outcomes and identifying which populations benefit most from these therapies.
In terms of age, BTK inhibitors therapies are primarily used in older adults,...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian